Medindia

X

N1 Technologies Inc. Posts Strong 3Q Results

Friday, November 4, 2016 Corporate News J E 4
Advertisement

BELIZE CITY, Belize, Nov. 4, 2016 /PRNewswire/ -- The directors and management of N1 Technologies Inc. (OTC PINK: NTCHF) today reported results for the fiscal 2016 third quarter ended September 30, 2016.  Net assets for the fiscal 2016 third quarter were $15,553,500 a dramatic increase over the previous quarter.  "We have made great progress in executing our transformation agenda as a Biotechnology focused company.  Our solid first three quarters of 2016 positions us well to deliver our full year 2016 outlook and 2017 Financial targets," commented Steve Lovern, President & CEO.  "Our focus on the Viritron Biopharmaceutical treatments currently under development, costs and overall restructuring have placed us in a good environment to drive strong expansion and earnings growth.  Our continued investment in our established brands, supply chain, sales and distribution capabilities continue to improve. This builds on our overall abilities to drive sustainable revenue and earnings growth."

N1Technologies Inc. Q3 Financial Results here:  http://www.otcmarkets.com/financialReportViewer?symbol=NTCHF&id=162036

NEW MISSIONN1 Technologies Inc. is a Global leader in the Research & Development of nanotechnology innovations, in the fields of nanotechnology and Biotechnology. The company has evolved since 2013 into a pure Bio-Tech enterprise. Originally the company manufactured a small number of its patented nanotechnology based products and marketed them to a worldwide consumer base. Over the last year the company has focused on R&D for future licensing of it's patented Viritron VDX, VPN and Mini Lab anti-bacterial treatments for Staphylococcus and Streptococcus bacterial infections. The company intends to enter this $30 Billion dollar market as a major supplier of anti-bacterial Genetically Modified Organisms, that offer an effective treatment for life threatening infections. "We have a unique strategy and exciting way to quickly monetize our R&D efforts by marketing our treatments to areas of the world desperate for effective anti-bacterial treatments. This strategy creates early patent value and great potential for our shareholders," says Mr. Lovern. 

FORWARD-LOOKING INFORMATIONCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

http://www.N1Technologies.com

RELATED LINKSEmail:  info@N1Technologies.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/n1-technologies-inc-posts-strong-3q-results-300357390.html

SOURCE N1 Technologies Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Seegene and Hologic Form Worldwide Collaboration t...
S
Uberification of Ambulance, Blood Bank, and Health...